NASDAQ:CLVS

Clovis Oncology - CLVS Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range: $0.08
▼
$0.10
50-Day Range: $0.08
▼
$1.09
52-Week Range: $0.08
▼
$3.32

Volume: 1.16 million shs
Average Volume: 8.88 million shs
Market Capitalization: $11.60 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About Clovis Oncology (NASDAQ:CLVS) Stock

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Receive CLVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

CLVS Stock News Headlines

February 24, 2023 | marketbeat.com

Analysts Holding As Pfizer Waits On Two Phase 3 Studies (CLVS)

Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.

March 12, 2023 | bizjournals.com

Silicon Valley Bank, a 'strong supporter' of Colorado tech startups, closed by regulators

March 22, 2023 | Legacy Research (Affiliate) (Ad)

"Prepare for Five Years of Famine"

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast

January 30, 2023 | reuters.com

CLVS.O

January 18, 2023 | seekingalpha.com

CLVSQ Clovis Oncology, Inc.

January 13, 2023 | forbes.com

Clovis Oncology

January 3, 2023 | wsj.com

Firm Retention Summary: Clovis Oncology Inc.

December 12, 2022 | reuters.com

Cancer drugmaker Clovis files for bankruptcy, hit by falling sales

March 22, 2023 | Legacy Research (Affiliate) (Ad)

"Prepare for Five Years of Famine"

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast

December 12, 2022 | benzinga.com

Thinking about buying stock in Clovis Oncology, Bank of America, Rivian Automotive, Rent the Runway, or Vipshop Holdings?

December 12, 2022 | bizjournals.com

Boulder drugmaker Clovis Oncology files for bankruptcy

December 12, 2022 | finance.yahoo.com

Clovis Plans to Sell Cancer Drug to Novartis in Bankruptcy Deal

December 12, 2022 | finance.yahoo.com

Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid

December 12, 2022 | finance.yahoo.com

Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis

December 12, 2022 | benzinga.com

Cancer Focused Clovis Oncology Files For Bankruptcy

December 12, 2022 | seekingalpha.com

Clovis stock slumps amid Chapter 11 filing, to sell FAP-2286 to Novartis for $50M upfront

December 12, 2022 | marketwatch.com

Clovis Oncology Shares Fall Premarket After Bankruptcy Filing >CLVS

December 12, 2022 | finance.yahoo.com

Clovis Oncology stock slides 10% premarket after company files for bankruptcy

December 12, 2022 | finance.yahoo.com

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

December 12, 2022 | finance.yahoo.com

U.S. drugmaker Clovis files for Chapter 11 bankruptcy

December 12, 2022 | finance.yahoo.com

UPDATE 1-Cancer drugmaker Clovis files for bankruptcy, hit by falling sales

November 25, 2022 | finance.yahoo.com

Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why

November 21, 2022 | finance.yahoo.com

Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)

November 11, 2022 | finance.yahoo.com

Clovis Oncology Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

November 9, 2022 | finance.yahoo.com

Clovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing Looms

November 9, 2022 | finance.yahoo.com

Clovis Oncology stock slides 75% after biotech warns it will run out of cash by January of 2023

November 9, 2022 | reuters.com

Clovis Oncology says could file for bankruptcy in 'very near term'

See More Headlines

Receive CLVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

CLVS Company Calendar

Last Earnings: 11/03/2021
Today: 3/22/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:CLVS
CUSIP: 18946410
CIK: 1466301
Web: www.clovisoncology.com
Phone: 303-625-5000
Fax: 303-245-0360
Employees: N/A
Year Founded: 2009

Profitability

EPS (Most Recent Fiscal Year): ($1.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-264,520,000.00
Net Margins: -189.37%
Pretax Margin: -189.68%
Return on Equity: N/A
Return on Assets: -57.78%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.14
Quick Ratio: 0.12

Sales & Book Value

Annual Sales: $148.76 million
Price / Sales: 0.08
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.15) per share
Price / Book: -0.04

Miscellaneous

Outstanding Shares: 144,955,000
Free Float: 138,577,000
Market Cap: $11.60 million
Optionable: Optionable
Beta: 0.24

Social Links

Key Executives

Mr. Patrick J. Mahaffy MA (Age 55)
Co-Founder, Chief Exec. Officer, Pres and Exec. Director

Dr. Gillian C. Ivers-Read BSc (Age 64)
Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations

Mr. Daniel W. Muehl CPA (Age 54)
Sr. VP of Fin. and Principal Financial & Accounting Officer

Dr. Lindsey Rolfe BSc (Age 50)
MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance

Mr. Corwin Dale Hooks (Age 51)
Chief Commercial Officer and Sr. VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CLVS Stock - Frequently Asked Questions

Should I buy or sell Clovis Oncology stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CLVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares.
View CLVS analyst ratings or view top-rated stocks.
How were Clovis Oncology's earnings last quarter?: Clovis Oncology (NASDAQ:CLVS) announced its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.08. The biopharmaceutical company earned $37.92 million during the quarter, compared to analyst estimates of $38.73 million. During the same period last year, the company earned ($0.89) EPS.
What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO?: 12 employees have rated Clovis Oncology Chief Executive Officer Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among the company's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Clovis Oncology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA).

What is Clovis Oncology's stock symbol?: Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
Who are Clovis Oncology's major shareholders?: Clovis Oncology's stock is owned by many different retail and institutional investors. Top institutional investors include Jane Street Group LLC (0.00%), Aristeia Capital LLC (0.00%), Susquehanna International Group LLP (0.00%), Cutler Group LLC CA (0.00%), Bank of Montreal Can (0.00%) and Wolverine Asset Management LLC (0.00%). Insiders that own company stock include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, Thomas C Harding and Thomas C Harding.
View institutional ownership trends.
What is Clovis Oncology's stock price today?: One share of CLVS stock can currently be purchased for approximately $0.08.
How much money does Clovis Oncology make?: Clovis Oncology (NASDAQ:CLVS) has a market capitalization of $11.60 million and generates $148.76 million in revenue each year. The biopharmaceutical company earns $-264,520,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis.
How can I contact Clovis Oncology?: Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The official website for the company is www.clovisoncology.com. The biopharmaceutical company can be reached via phone at 303-625-5000, via email at bburkart@clovisoncology.com, or via fax at 303-245-0360.

This page (NASDAQ:CLVS) was last updated on 3/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Clovis Oncology - CLVS Stock Forecast, Price & News

About Clovis Oncology (NASDAQ:CLVS) Stock

CLVS Stock News Headlines

CLVS Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

CLVS Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info